Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Small Bone Innovations, a provider of products, technology and education for the small bone and joint sector of the orthopedic industry, has consolidated five separate agreements into a single new agreement on worldwide license, supply and distribution of Artelon products with Artimplant of Vastra Frolunda, Sweden.
Subscribe to our email newsletter
The new agreement addresses the five existing technologies and two applications in development of the Artelon spacer portfolio designed to treat arthritis within small bone and joints.
Small Bone Innovations (SBi) will no longer own exclusive rights to market and sell spacer products already cleared by the FDA and certain other products not yet introduced in the US market. SBi began marketing Artelon products in 2005.
In return, Artimplant has agreed to fund and provide increased clinical documentation on the performance of Artelon spacers, including patient studies. Artimplant will also receive a higher share of margins attributable to SBi sales of Artelon spacers.
The new agreement consolidating the five separate agreements is retroactive to January 1, 2009. The affected products include: Artelon CMC-I Spacer, Artelon CMC Spacer Arthro, and Artelon STT Spacer, marketed worldwide and the Artelon DRU Spacer and Artelon MTP Spacer marketed outside the US. Artelon is a registered trademark of Artimplant.
Anthony Viscogliosi, chairman and CEO of SBi, said: The new agreement provides increased incentives for both our companies to continue to build the Artelon brand that has already contributed so successfully to the development of our upper limb portfolio in the US.